TELA Bio, Inc.
NASDAQTELA Bio enters its Q1 2026 earnings call with an unusually charged setup: a near-50% weekly price surge, a preliminary revenue beat, and a sweeping board refresh — all landing in the same week. The catalyst is clear. On April 30, the company pre-announced Q1 revenue of approximately $19 million, beating its own prior guidance of $18.5 million. Simultaneously, TELA unveiled four…
TELA put-call ratio surges to 1.47, a 4.2 standard deviation move above the 20-day mean of 0.99, signaling extreme options bearishness as the stock rallies 37.7% over one week.
Snapshot as of 7 May 2026
TELA Bio enters its Q1 2026 earnings call with an unusually charged setup: a near-50% weekly price surge, a preliminary revenue beat, and a sweeping board refresh — all landing in the same week. The catalyst is clear.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TELA — free to start on ORTEX.
Sign up for free →Open TELA on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live TELA data →